An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
B. D. Quinlan, W. Li, H. Mou, L. Zhang, J. Chang, S. Peng, A. Ojha, R. Tavora, M. S. Parcells, G. G. Luo, W. Li, G. Zhong, H. Choe, M. Farzan
This paper shows that an engineered RBD with glycosylation sites improves immunogenicity and expression efficiency in SARS-CoV-2 vaccines.
bioRxiv · Nov 18, 2020Microbiology